Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months.

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a clinical ...

Overall survival was significantly better with the combination therapy, achieving 23.1 months versus 19.6 months with PHP alone. Combination therapy of percutaneous hepatic perfusion with immune ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that ...

Patients with untreated advanced melanoma do not appear to gain a survival advantage from the addition of a cancer vaccine to pembrolizumab, suggests a trial.

Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...